Understanding the UK Psychoactive Substances Act

被引：12

作者：

Hill, Raymond G. ^{[1
]}

机构：

[1] Imperial Coll, Fac Med, Commonwealth Bldg,Hammersmith Campus,Du Cane Rd, London, England

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2020年 / 86卷 / 03期

关键词：

drug legislation; novel psychoactive substances;

D O I：

10.1111/bcp.14168

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This review paper is based on a talk given at the British Pharmaceutical Society Winter Meeting in 2018 derived from the Home Office Report on the workings of the UK Psychoactive Substances Act (PSA) published in November 2018. The review deals with the context in which the PSA 2016 arose and how this piece of legislation differs from other UK drug regulations. It attempts to put the PSA in context with other control schemes being instituted around the world and to assess the success of the Act in its first 2 years of implementation. For more details the reader is referred to Review of the Psychoactive Substances Act 2016, Home Office, November 2018.

引用

页码：499 / 504

页数：6

共 50 条

[1] Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016
Deen, Adrian A.
Claridge, Hugh
Treble, Richard D.
Hamnett, Hilary J.
Copeland, Caroline S.
[J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2021, 35 (11) : 1315 - 1323
[2] Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances
Deligianni, Elena
Daniel, Omari J.
Corkery, John M.
Schifano, Fabrizio
Lione, Lisa A.
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (03) : 505 - 516
[3] Change in the new psychoactive substances associated with Emergency Department acute toxicity presentations associated with the introduction of the UK 2016 Psychoactive Substances Act
Webb, Nicholas E.
Wood, David M.
Greene, Shaun L.
Hunter, Laura J.
Archer, John R. H.
Dines, Alison M.
Dargan, Paul I.
[J]. CLINICAL TOXICOLOGY, 2019, 57 (01) : 36 - 41
[4] Use of psychoactive substances and the seriousness of criminal act
Sun, F
Cousineau, MM
Brochu, S
White, ND
[J]. CANADIAN JOURNAL OF CRIMINOLOGY AND CRIMINAL JUSTICE, 2004, 46 (01) : 1 - 26
[5] Impact of the UK Psychoactive Substances Act 2016 on Emergency Department presentations related to synthetic cannabinoid receptor agonists (SCRAs), cathinones and other new psychoactive substances
Webb, Nicholas E.
Wood, David M.
Archer, John R. H.
Dines, Alison
Dargan, Paul I.
[J]. CLINICAL TOXICOLOGY, 2018, 56 (06) : 456 - 456
[6] Addressing the public health impact of new psychoactive substances: early analysis of the effects of the UK's Psychoactive Substances Act on poisons centre enquiries related to drugs of misuse
Al Banaa, Israa
Hawkins, Leonard C.
Lupton, David J.
Jackson, Gillian
Sandilands, Euan A.
Thompson, John P.
Bradberry, Sally M.
Hill, Simon L.
Thomas, Simon H. L.
[J]. CLINICAL TOXICOLOGY, 2017, 55 (05) : 440 - 441
[7] Effect of the UK Psychoactive Substances Act 2016 on episodes of toxicity related to new psychoactive substances as reported to the National Poisons Information Service. A time series analysis
Al-Banaa, I
Hawkins, L.
Hill, S. L.
Lupton, D. J.
Jackson, G.
Sandilands, E. A.
Bradberry, S. M.
Thompson, J. P.
Rushton, S.
Thomas, S. H. L.
[J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 77
[8] NEW PSYCHOACTIVE SUBSTANCES IN IRELAND FOLLOWING THE CRIMINAL JUSTICE (PSYCHOACTIVE SUBSTANCES) ACT-WHY ALL THE PESSIMISM?
Smyth, Bobby P.
[J]. ADDICTION, 2017, 112 (09) : 1686 - 1686
[9] The New Zealand Psychoactive Substances Act (PSA): a policy breakthrough or just a symbolic act?
Bretteville-Jensen, Anne Line
[J]. ADDICTION, 2014, 109 (10) : 1590 - 1591
[10] Phantom menace: novel psychoactive substances and the UK Armed Forces
Hunter, Alys H.
Ayres, T.
Moreland, N.
Cox, A.
[J]. JOURNAL OF THE ROYAL ARMY MEDICAL CORPS, 2018, 164 (06) : 450 - 457

← 1 2 3 4 5 →